Brief: Ascentage Pharma Group Says Lisaftoclax Granted Breakthrough Therapy Designation In China
21/10/2026 02:17
BRIEF-Ascentage Pharma Group Says Lisaftoclax Granted Breakthrough Therapy Designation In China Oct 21 (Reuters) - Ascentage Pharma Group International 6855.HK:
LISAFTOCLAX GRANTED BREAKTHROUGH THERAPY DESIGNATION IN CHINA FOR TREATMENT-NAÏVE CLL/SLL
Further company coverage: 6855.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Ascentage Pharma International
See all newsBrief: Ascentage Pharma Group Says Lisaftoclax Granted Breakthrough Therapy Designation In China
China's Ascentage Pharma climbs as chairman buys shares on market
Brief: Ascentage Pharma Group International's Chairman Buys 38,630 Shares
Brief: Ascentage Pharma Group International Posts H1 Net Loss Attributable RMB816.7 Million
China's Ascentage Pharma H1 revenue rises 29% on Lisaftoclax ramp-up